Search

Your search keyword '"Komajda M"' showing total 1,091 results
Start Over Author "Komajda M"
1,091 results on '"Komajda M"'

1. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

Author

Packer, M, Anker, S, Butler, J, Filippatos, G, Pocock, S, Zannad, F, Ferreira, JP, Brueckmann, M, George, J, Jamal, W, Welty, FK, Palmer, M, Clayton, T, Parhofer, KG, Pedersen, TR, Greenberg, B, Konstam, MA, Lees, KR, Carson, P, Doehner, W, Miller, A, Haas, M, Pehrson, S, Komajda, M, Anand, I, Teerlink, J, Rabinstein, A, Steiner, T, Kamel, H, Tsivgoulis, G, Lewis, J, Freston, J, Kaplowitz, N, Mann, J, Petrie, J, Perrone, S, Nicholls, S, Janssens, S, Bocchi, E, Giannetti, N, Verma, S, Zhang, J, Spinar, J, Seronde, M-F, Boehm, M, Merkely, B, Chopra, V, Senni, M, Taddi, S, Tsutsui, H, Choi, D-J, Chuquiure, E, La Rocca, HPB, Ponikowski, P, Juanatey, JRG, Squire, I, Januzzi, J, Pina, I, Bernstein, R, Cheung, A, Green, J, Kaul, S, Lam, C, Lip, G, Marx, N, McCullough, P, Mehta, C, Rosenstock, J, Sattar, N, Scirica, B, Shah, S, Wanner, C, Aizenberg, D, Cartasegna, L, Colombo Berra, F, Colombo, H, Fernandez Moutin, M, Glenny, J, Alvarez Lorio, C, Anauch, D, Campos, R, Facta, A, Fernandez, A, Ahuad Guerrero, R, Lobo Márquez, L, Leon de la Fuente, RA, Mansilla, M, Hominal, M, Hasbani, E, Najenson, M, Moises Azize, G, Luquez, H, Guzman, L, Sessa, H, Amuchástegui, M, Salomone, O, Perna, E, Piskorz, D, Sicer, M, Perez de Arenaza, D, Zaidman, C, Nani, S, Poy, C, Resk, J, Villarreal, R, Majul, C, Smith Casabella, T, Sassone, S, Liberman, A, Carnero, G, Caccavo, A, Berli, M, Budassi, N, Bono, J, Alvarisqueta, A, Amerena, J, Kostner, K, Hamilton, A, Begg, A, Beltrame, J, Colquhoun, D, Gordon, G, Sverdlov, A, Vaddadi, G, Wong, J, Coller, J, Prior, D, Friart, A, Leone, A, Vervoort, G, Timmermans, P, Troisfontaines, P, Franssen, C, Sarens, T, Vandekerckhove, H, Van De Borne, P, Chenot, F, De Sutter, J, De Vuyst, E, Debonnaire, P, Dupont, M, Pereira Dutra, O, Canani, LH, Vieira Moreira, MdC, de Souza, W, Backes, LM, Maia, L, De Souza Paolino, B, Manenti, ER, Saporito, W, Villaça Guimarães Filho, F, Franco Hirakawa, T, Saliba, LA, Neuenschwander, FC, de Freitas Zerbini, CA, Gonçalves, G, Gonçalves Mello, Y, Ascenção de Souza, J, Beck da Silva Neto, L, Bocchi, EA, Da Silveira, J, de Moura Xavier Moraes Junior, JB, de Souza Neto, JD, Hernandes, M, Finimundi, HC, Sampaio, CR, Vasconcellos, E, Neves Mancuso, FJ, Noya Rabelo, MM, Rodrigues Bacci, M, Santos, F, Vidotti, M, Simões, MV, Gomes, FL, Vieira Nascimento, C, Precoma, D, Helfenstein Fonseca, FA, Ribas Fortes, JA, Leães, PE, Campos de Albuquerque, D, Kerr Saraiva, JF, Rassi, S, Alves da Costa, FA, Reis, G, Zieroth, S, Dion, D, Savard, D, Bourgeois, R, Constance, C, Anderson, K, Leblanc, M-H, Yung, D, Swiggum, E, Pliamm, L, Pesant, Y, Tyrrell, B, Huynh, T, Spiegelman, J, Lavoie, J-P, Hartleib, M, Bhargava, R, Straatman, L, Virani, S, Costa-Vitali, A, Hill, L, Heffernan, M, Khaykin, Y, Ricci, J, Senaratne, M, Zhai, A, Lubelsky, B, Toma, M, Yao, L, McKelvie, R, Noronha, L, Babapulle, M, Pandey, A, Curnew, G, Lavoie, A, Berlingieri, J, Kouz, S, Lonn, E, Chehayeb, R, Zheng, Y, Sun, Y, Cui, H, Fan, Z, Han, X, Jiang, X, Tang, Q, Zhou, J, Zheng, Z, Zhang, X, Zhang, N, Zhang, Y, Shen, A, Yu, J, Ye, J, Yao, Y, Yan, J, Xu, X, Wang, Z, Ma, J, Li, Y, Li, S, Lu, S, Kong, X, Song, Y, Yang, G, Yao, Z, Pan, Y, Guo, X, Sun, Z, Dong, Y, Zhu, J, Peng, D, Yuan, Z, Lin, J, Yin, Y, Jerabek, O, Burianova, H, Fiala, T, Hubac, J, Ludka, O, Monhart, Z, Vodnansky, P, Zeman, K, Foldyna, D, Krupicka, J, Podpera, I, Busak, L, Radvan, M, Vomacka, Z, Prosecky, R, Cifkova, R, Durdil, V, Vesely, J, Vaclavik, J, Cervinka, P, Linhart, A, Brabec, T, Miklik, R, Bourhaial, H, Olbrich, H-G, Genth-Zotz, S, Kemala, E, Lemke, B, Böhm, M, Schellong, S, Rieker, W, Heitzer, T, Ince, H, Faghih, M, Birkenfeld, A, Begemann, A, Ghanem, A, Ujeyl, A, von Haehling, S, Dorsel, T, Bauersachs, J, Prull, M, Weidemann, F, Darius, H, Nickenig, G, Wilke, A, Sauter, J, Rauch-Kroehnert, U, Frey, N, Schulze, CP, König, W, Maier, L, Menzel, F, Proskynitopoulos, N, Ebert, H-H, Sarnighausen, H-E, Düngen, H-D, Licka, M, Stellbrink, C, Winkelmann, B, Menck, N, López-Sendón, JL, de la Fuente Galán, L, Delgado Jiménez, JF, Manito Lorite, N, Pérez de Juan Romero, M, Galve Basilio, E, Cereto Castro, F, González Juanatey, JR, Gómez, JJ, Sanmartín Fernández, M, Garcia-Moll Marimon, X, Pascual Figal, D, Bover Freire, R, Bonnefoy Cudraz, E, Jobbe Duval, A, Tomasevic, D, Habib, G, Isnard, R, Picard, F, Khanoyan, P, Dubois-Rande, J-L, Galinier, M, Roubille, F, Alexandre, J, Babuty, D, Delarche, N, Berneau, J-B, Girerd, N, Saxena, M, Rosano, G, Yousef, Z, Clifford, C, Arden, C, Bakhai, A, Boos, C, Jenkins, G, Travill, C, Price, D, Koenyves, L, Lakatos, F, Matoltsy, A, Noori, E, Zilahi, Z, Andrassy, P, Kancz, S, Simon, G, Sydo, T, Vorobcsuk, A, Kiss, RG, Toth, K, Szakal, I, Nagy, L, Barany, T, Nagy, A, Szolnoki, E, Chopra, VK, Mandal, S, Rastogi, V, Shah, B, Mullasari, A, Shankar, J, Mehta, V, Oomman, A, Kaul, U, Komarlu, S, Kahali, D, Bhagwat, A, Vijan, V, Ghaisas, NK, Mehta, A, Kashyap, J, Kothari, Y, TaddeI, S, Scherillo, M, Zacà, V, Genovese, S, Salvioni, A, Fucili, A, Fedele, F, Cosmi, F, Volpe, M, Mazzone, C, Esposito, G, Doi, M, Yamamoto, H, Sakagami, S, Oishi, S, Yasaka, Y, Tsuboi, H, Fujino, Y, Matsuoka, S, Watanabe, Y, Himi, T, Ide, T, Ichikawa, M, Kijima, Y, Koga, T, Yuda, S, Fukui, K, Kubota, T, Manita, M, Fujinaga, H, Matsumura, T, Fukumoto, Y, Kato, R, Kawai, Y, Hiasa, G, Kazatani, Y, Mori, M, Ogimoto, A, Inoko, M, Oguri, M, Kinoshita, M, Okuhara, K, Watanabe, N, Ono, Y, Otomo, K, Sato, Y, Matsunaga, T, Takaishi, A, Miyagi, N, Uehara, H, Takaishi, H, Urata, H, Kataoka, T, Matsubara, H, Matsumoto, T, Suzuki, T, Takahashi, N, Imamaki, M, Yoshitama, T, Saito, T, Sekino, H, Furutani, Y, Koda, M, Shinozaki, T, Hirabayashi, K, Tsunoda, R, Yonezawa, K, Hori, H, Yagi, M, Arikawa, M, Hashizume, T, Ishiki, R, Koizumi, T, Nakayama, K, Taguchi, S, Nanasato, M, Yoshida, Y, Tsujiyama, S, Nakamura, T, Oku, K, Shimizu, M, Suwa, M, Momiyama, Y, Sugiyama, H, Kobayashi, K, Inoue, S, Kadokami, T, Maeno, K, Kawamitsu, K, Maruyama, Y, Nakata, A, Shibata, T, Wada, A, Cho, H-J, Na, JO, Yoo, B-S, Choi, J-O, Hong, SK, Shin, J-H, Cho, M-C, Han, SH, Jeong, J-O, Kim, J-J, Kang, SM, Kim, D-S, Kim, MH, Llamas Esperon, G, Illescas Díaz, J, Fajardo Campos, P, Almeida Alvarado, J, Bazzoni Ruiz, A, Echeverri Rico, J, Lopez Alcocer, I, Valle Molina, L, Hernandez Herrera, C, Calvo Vargas, C, Padilla Padilla, FG, Rodriguez Briones, I, Chuquiure Valenzuela, EJJR, Aguilera Real, ME, Carrillo Calvillo, J, Alpizar Salazar, M, Cervantes Escárcega, JL, Velasco Sanchez, R, Al - Windy, N, van Heerebeek, L, Bellersen, L, Brunner-La Rocca, H-P, Post, J, Linssen, GCM, van de Wetering, M, Peters, R, van Stralen, R, Groutars, R, Smits, P, Yilmaz, A, Kok, WEM, Van der Meer, P, Dijkmans, P, Troquay, R, van Alem, AP, Van de Wal, R, Handoko, L, Westendorp, ICD, van Bergen, PFMM, Rensing, BJWM, Hoogslag, P, Kietselaer, B, Kragten, JA, den Hartog, FR, Alings, A, Danilowicz-Szymanowicz, L, Raczak, G, Piesiewicz, W, Zmuda, W, Kus, W, Podolec, P, Musial, W, Drelich, G, Kania, G, Miekus, P, Mazur, S, Janik, A, Spyra, J, Peruga, J, Balsam, P, Krakowiak, B, Szachniewicz, J, Ginel, M, Grzybowski, J, Chrustowski, W, Wojewoda, P, Kalinka, A, Zurakowski, A, Koc, R, Debinski, M, Fil, W, Kujawiak, M, Forys, J, Kasprzak, M, Krol, M, Michalski, P, Mirek-Bryniarska, E, Radwan, K, Skonieczny, G, Stania, K, Skoczylas, G, Madej, A, Jurowiecki, J, Firek, B, Wozakowska-Kaplon, B, Cymerman, K, Neutel, J, Adams, K, Balfour, P, Deswal, A, Djamson, A, Duncan, P, Hong, M, Murray, C, Rinde-Hoffman, D, Woodhouse, S, MacNevin, R, Rama, B, Broome-Webster, C, Kindsvater, S, Abramov, D, Barettella, M, Pinney, S, Herre, J, Cohen, A, Vora, K, Challappa, K, West, S, Baum, S, Cox, J, Jani, S, Karim, A, Akhtar, A, Quintana, O, Paukman, L, Goldberg, R, Bhatti, Z, Budoff, M, Bush, E, Potler, A, Delgado, R, Ellis, B, Dy, J, Fialkow, J, Sangrigoli, R, Ferdinand, K, East, C, Falkowski, S, Donahoe, S, Ebrahimi, R, Kline, G, Harris, B, Khouzam, R, Jaffrani, N, Jarmukli, N, Kazemi, N, Koren, M, Friedman, K, Herzog, W, Silva Enciso, J, Cheung, D, Grover-McKay, M, Hauptman, P, Mikhalkova, D, Hegde, V, Hodsden, J, Khouri, S, McGrew, F, Littlefield, R, Bradley, P, McLaurin, B, Lupovitch, S, Labin, I, Rao, V, Leithe, M, Lesko, M, Lewis, N, Lombardo, D, Mahal, S, Malhotra, V, Dauber, I, Banerjee, A, Needell, J, Miller, G, Paladino, L, Munuswamy, K, Nanna, M, McMillan, E, Mumma, M, Napoli, M, Nelson, W, O'Brien, T, Adlakha, A, Onwuanyi, A, Serota, H, Schmedtje, J, Paraschos, A, Potu, R, Sai-Sudhakar, C, Saltzberg, M, Sauer, A, Shah, P, Skopicki, H, Bui, H, Carr, K, Stevens, G, Tahirkheli, N, Tallaj, J, Yousuf, K, Trichon, B, Welker, J, Tolerico, P, Vest, A, Vivo, R, Wang, X, Abadier, R, Dunlap, S, Weintraub, N, Malik, A, Kotha, P, Zaha, V, Kim, G, Uriel, N, Greene, T, Salacata, A, Arora, R, Gazmuri, R, Kobayashi, J, Iteld, B, Vijayakrishnan, R, Dab, R, Mirza, Z, Marques, V, Nallasivan, M, Bensimhon, D, Peart, B, Saint-Jacques, H, Barringhaus, K, Contreras, J, Gupta, A, Koneru, S, Nguyen, V, Verma, Subodh, Dhingra, Nitish K, Butler, Javed, Anker, Stefan D, Ferreira, Joao Pedro, Filippatos, Gerasimos, Januzzi, James L, Lam, Carolyn S P, Sattar, Naveed, Peil, Barbara, Nordaby, Matias, Brueckmann, Martina, Pocock, Stuart J, Zannad, Faiez, and Packer, Milton

Published
2022
Full Text
View/download PDF

3. Is karate a safe and effective method of cardiac rehabilitation in patients with heart failure and reduced ejection fraction? The KAREAD trial

Author

Duc, P., primary, Iliou, M.-C., additional, Duc, B.-V., additional, Audrey, F., additional, Ledru, F., additional, Sacco, E., additional, Chatellier, G., additional, Lamar-Tanguy, A., additional, Jagu, A., additional, Garcon, P., additional, Antakly, Y., additional, Moeuf, Y., additional, Standish, B., additional, Carbonnie, R.A., additional, Parpaillon, J., additional, Komajda, M., additional, and Cador, R., additional

Published
2024
Full Text
View/download PDF

5. Do surgical or cloth masks alter ventilatory parameters during submaximal exercise? The PAM randomized trial

Author

Duc, P., primary, Duc, B.-V., additional, Fels, A., additional, Sacco, E., additional, Chatellier, G., additional, Iliou., M.-C., additional, Sosner, P., additional, Jagu, A., additional, Antakly, Y., additional, Garcon, P., additional, Moeuf, Y., additional, Standish, B., additional, Carbonnier, A., additional, Parpaillon, J., additional, Komajda, M., additional, and Cador, R., additional

Published
2024
Full Text
View/download PDF

9. Randomized Trials Fit for the 21st Century: A Joint Opinion From the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation

Author

Bowman, L, Weidinger, F, Albert, MA, Fry, ETA, Pinto, FJ, Achenbach, S, Casadei, B, Collins, R, Devereaux, PJ, Douglas, PS, Frobert, O, Goto, S, Grines, C, Harrington, RA, Haynes, R, Hochman, JS, James, S, Kirchhof, P, Komajda, M, Lam, CSP, Landray, M, Maggioni, A, Mcmurray, J, Medhurst, N, Neal, B ; https://orcid.org/0000-0002-0490-7465, Rydén, L, Thiele, H, Van Gelder, I, Wallentin, L, Yusuf, S, Zannad, F, Bowman, L, Weidinger, F, Albert, MA, Fry, ETA, Pinto, FJ, Achenbach, S, Casadei, B, Collins, R, Devereaux, PJ, Douglas, PS, Frobert, O, Goto, S, Grines, C, Harrington, RA, Haynes, R, Hochman, JS, James, S, Kirchhof, P, Komajda, M, Lam, CSP, Landray, M, Maggioni, A, Mcmurray, J, Medhurst, N, Neal, B ; https://orcid.org/0000-0002-0490-7465, Rydén, L, Thiele, H, Van Gelder, I, Wallentin, L, Yusuf, S, and Zannad, F

Published
2023

10. Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial

Author

Carson, P. Teerlink, J.R. Komajda, M. Anand, I. Anker, S.D. Butler, J. Doehner, W. Ferreira, J.P. Filippatos, G. Haass, M. Miller, A. Pehrson, S. Pocock, S.J. Schnaidt, S. Schnee, J.M. Zannad, F. Packer, M. and Carson, P. Teerlink, J.R. Komajda, M. Anand, I. Anker, S.D. Butler, J. Doehner, W. Ferreira, J.P. Filippatos, G. Haass, M. Miller, A. Pehrson, S. Pocock, S.J. Schnaidt, S. Schnee, J.M. Zannad, F. Packer, M.

Abstract

Background: There is limited published information on outcome adjudication in heart failure (HF). Objectives: The authors sought to compare investigator reports (IRs) to a Clinical Events Committee (CEC) and the impact of SCTI (Standardized Clinical Trial Initiative) criteria. Methods: In the EMPEROR-Reduced trial, the authors compared IRs to the CEC for concordance; treatment effect on primary composite outcome events; and the components first event hospitalization primarily for HF or cardiovascular mortality (CVM), prognosis after hospitalization for heart failure (HHF), total HHFs, and trial duration with and without SCTI criteria. Results: The CEC confirmed 76.3% of IR events for the primary outcome (CVM: 89.1%; HHF: 73.7%). The HR for treatment effect did not differ between adjudication methods for the primary outcome (IR: 0.75 [95% CI: 0.66-0.85]; CEC: 0.75 [95% CI: 0.65-0.86]), its components, or total HHFs. The prognosis after first HHF for all-cause mortality and CVM also did not differ between IR or CEC. Interestingly, IR primary HHF with different CEC primary cause had the highest subsequent fatal event rate. Full SCTI criteria were present in 90% of CEC HHFs—with a similar treatment effect to non-SCTI. The IR primary event reached the protocol target number (841) 3 months earlier than CEC (4 months with full SCTI criteria). Conclusions: Investigator adjudication is an alternative to a CEC with similar accuracy and faster event accumulation. The use of granular (SCTI) criteria did not improve trial performance. Finally, our data suggest that consideration be given to broadening the HHF definition to include “for or with” worsening disease. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction [EMPEROR-Reduced]; NCT03057977) © 2023 The Authors

Published
2023

11. Care pathway of a cohort of hospitalized heart failure patients in Paris (Ile de France). Insight from SNDS data base at one year.

Author

Abassade, P., Fleury, L., Fels, A., Chatellier, G., Sacco, E., Beaussier, H., Komajda, M., and Cador, R.

Abstract

Congestive heart failure (CHF) is associated with prolonged and recurrent hospitalizations, the prognosis remains poor. Analysis of epidemiology, healthcare consumption and prognosis at one year of a cohort of hospitalized patients for congestive heart failure in Saint Joseph Hospital (SHJ), using the SNDS data base (National data base). From September 2016 to September 2018 all patients hospitalized for CHF in SJH were included. CHF was assessed by ESC criteria. Clinical and biological data were collected from the electronic health record. The follow up was one year. At this date, using SNDS data base, were collected mortality, re-hospitalization for CHF, re-hospitalization for other reason, drug prescription, healthcare consumption. Six hundred and fifteen patients were included, 287 female (46.7%), the mean age 78.43 years (±11.10). Mean Ejection Fraction (EF) was 45.3% (±15.0), 199patients (32.36%) with preserved EF, ischemic disease for 370 patients (60.2%), 275 (44.7%) were in sinus rhythm. At discharge median BNP was 350.0 ng/ml [174;770], mean Hemoglobin 12.4 g/dl (±1.82), 323 patients (52.5%) with anemia (Hb < 12 g/dl). At one year the rates of drug consumption were for Conversion enzymeinhibitor or Angiotensine receptor antagonist 65.0%, loop diuretics 93.0%, spironolactone/eplerenone 27.7%, beta blocker 70.2%, oral direct anticoagulant34.9%, AVK 29.1%, antiplatelet agent 42.3%. At one year 563 patients (91.5%) had a general practitioner (GP) consultation (CS), the median number of GP CSwas 11 [7.0; 16.0], the median delay for the first GP CS was 13.0 days [6.0; 39.5], 400 (65%) had a cardiologist (C) CS, the median delay for the first C CSwas 55 days [28.0; 116.0]. Re-hospitalization rate for CHF was 36.75%, median delay 55 days [20.0; 156.2], 431 (70.0%) were re hospitalized for other reason atone year, median delay 61.0 days [20.0; 156.0], median number 2.0 [1.0; 4.0]. The mortality rate was 18.21%. The median delay of death occurrence was 137.0days [63.7; 240.0]. The composite index death or re-hospitalization concerned 484 (78.7%) patients of our cohort (Fig. 1). Our study confirmed that the CHF population had a poor prognosis despite health care policy and programs. Qualitative and quantitative improvement of the care pathway are needed. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

15. Dilated Cardiomyopathy – Results, Conclusions and Perspectives

Author

Garnier, S, Harakalova, M, Weiss, S, Mokry, M, Isnard, R, Duboscq-Bidot, L, Komajda, M, Cambien, F, Deleuze, J-F, Dörr, M, Asselbergs F, W, Villard, E, Trégouët, D-A, Charron, P, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Utrecht University [Utrecht], Universität Greifswald - University of Greifswald, Centre National de Recherche en Génomique Humaine (CNRGH), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratory of Excellence GENMED [Paris] (Medical Genomics), University of Medicine Greifswald, German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), and GenMed consortuium

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience

Published
2022

16. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

Author

Packer M., Butler J., Filippatos G. S., Jamal W., Salsali A., Schnee J., Kimura K., Zeller C., George J., Brueckmann M., Anker S. D., Zannad F., Perrone S., Nicholls S., Janssens S., Bocchi E., Giannetti N., Verma S., Jian Z., Spinar J., Seronde M. -F., Bohm M., Merkely B., Chopra V., Senni M., Taddei S., Tsutsui H., Choi D. -J., Chuquiure E., La Rocca H. P. B., Ponikowski P., Juanatey J. R. G., Squire I., Januzzi J., Pina I., Pocock S. J., Carson P., Doehner W., Miller A., Haas M., Pehrson S., Komajda M., Anand I., Teerlink J., Rabinstein A., Steiner T., Kamel H., Tsivgoulis G., Lewis J., Freston J., Kaplowitz N., Mann J., Petrie M., Bernstein R., Cheung A., Green J., Kaul S., Ping C. L. S., Lip G., Marx N., McCullough P., Mehta C., Rosenstock J., Sattar N., Scirica B., Wanner C., Welty F. K., Parhofer K. G., Clayton T., Pedersen T. R., Lees K. R., Konstam M. A., Greenberg B., Palmer M., Packer, M, Butler, J, Filippatos, G, Jamal, W, Salsali, A, Schnee, J, Kimura, K, Zeller, C, George, J, Brueckmann, M, Anker, S, Zannad, F, Perrone, S, Nicholls, S, Janssens, S, Bocchi, E, Giannetti, N, Verma, S, Jian, Z, Spinar, J, Seronde, M, Bohm, M, Merkely, B, Chopra, V, Senni, M, Taddei, S, Tsutsui, H, Choi, D, Chuquiure, E, La Rocca, H, Ponikowski, P, Juanatey, J, Squire, I, Januzzi, J, Pina, I, Pocock, S, Carson, P, Doehner, W, Miller, A, Haas, M, Pehrson, S, Komajda, M, Anand, I, Teerlink, J, Rabinstein, A, Steiner, T, Kamel, H, Tsivgoulis, G, Lewis, J, Freston, J, Kaplowitz, N, Mann, J, Petrie, M, Bernstein, R, Cheung, A, Green, J, Kaul, S, Ping, C, Lip, G, Marx, N, Mccullough, P, Mehta, C, Rosenstock, J, Sattar, N, Scirica, B, Wanner, C, Welty, F, Parhofer, K, Clayton, T, Pedersen, T, Lees, K, Konstam, M, Greenberg, B, Palmer, M, RS: Carim - H02 Cardiomyopathy, MUMC+: MA Med Staf Spec Cardiologie (9), Cardiologie, and RS: CARIM - R2.02 - Cardiomyopathy

Subjects
MECHANISM, Trial design, medicine.medical_specialty, Cardiac & Cardiovascular Systems, NA+/H+-EXCHANGER, Heart failure, Type 2 diabetes, 030204 cardiovascular system & hematology, Diabete, SGLT2 INHIBITORS, Reduced ejection fraction, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Glucosides, Internal medicine, Diabetes mellitus, Clinical endpoint, Empagliflozin, Humans, Medicine, Benzhydryl Compounds, Dapagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Randomized Controlled Trials as Topic, RISK, Canagliflozin, OUTCOMES, Science & Technology, Ejection fraction, diabetes, business.industry, Diabetes, Stroke Volume, SGLT2 inhibitor, medicine.disease, chemistry, HOSPITALIZATION, Chronic Disease, Cardiovascular System & Cardiology, Cardiology, Cardiology and Cardiovascular Medicine, business, Life Sciences & Biomedicine, medicine.drug
Abstract

Drugs that inhibit the sodium-glucose co-transporter 2 (SGLT2) have been shown to reduce the risk of hospitalizations for heart failure in patients with type 2 diabetes. In populations that largely did not have heart failure at the time of enrolment, empagliflozin, canagliflozin and dapagliflozin decreased the risk of serious new-onset heart failure events by ≈30%. In addition, in the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of both pump failure and sudden deaths, the two most common modes of death among patients with heart failure. In none of the three trials could the benefits of SGLT2 inhibitors on heart failure be explained by the actions of these drugs as diuretics or anti-hyperglycaemic agents. These observations raise the possibility that SGLT2 inhibitors could reduce morbidity and mortality in patients with established heart failure, including those without diabetes. The EMPEROR-Reduced trial is enrolling ≈3600 patients with heart failure and a reduced left ventricular ejection fraction (≤ 40%), half of whom are expected not to have diabetes. Patients are being randomized to placebo or empagliflozin 10 mg daily, which is added to all appropriate treatment with inhibitors of the renin-angiotensin system and neprilysin, beta-blockers and mineralocorticoid receptor antagonists. The primary endpoint is the time-to-first event analysis of the combined risk of cardiovascular death and hospitalization for heart failure, but the trial will also evaluate the effects of empagliflozin on renal function, cardiovascular death, all-cause mortality, and recurrent hospitalization events. By adjusting eligibility based on natriuretic peptide levels to the baseline ejection fraction, the trial will preferentially enrol high-risk patients. A large proportion of the participants is expected to have an ejection fraction

Published
2019
Full Text
View/download PDF

17. Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis

Author

Jackson, Colette E., Castagno, Davide, Maggioni, Aldo P., Køber, Lars, Squire, Iain B., Swedberg, Karl, Andersson, Bert, Richards, A. Mark, Bayes-Genis, Antoni, Tribouilloy, Christophe, Dobson, Joanna, Ariti, Cono A., Poppe, Katrina K., Earle, Nikki, Whalley, Gillian, Pocock, Stuart J., Doughty, Robert N., McMurray, John J.V., Berry, C., Doughty, R., Granger, C., Køber, L., Massie, B., McAlister, F., McMurray, J., Pocock, S., Poppe, K., Swedberg, K., Somaratne, J., Whalley, G., Ahmed, A., Andersson, B., Bayes-Genis, A., Berry, C., Cowie, M., Cubbon, R., Doughty, R., Ezekowitz, J., Gonzalez-Juanatey, J., Gorini, M., Gotsman, I., Grigorian-Shamagian, L., Guazzi, M., Kearney, M., Køber, L., Komajda, M., di Lenarda, A., Lenzen, M., Lucci, D., Macín, S., Madsen, B., Maggioni, A., Martínez-Sellés, M., McAlister, F., Oliva, F., Poppe, K., Rich, M., Richards, M., Senni, M., Squire, I., Taffet, G., Tarantini, L., Tribouilloy, C., Troughton, R., Tsutsui, H., Whalley, G., Doughty, R., Earle, N., Gamble, G.D., Poppe, K., Whalley, G., Ariti, C., Dobson, J., Pocock, S., Poppe, K., Doughty, R.N., Whalley, G., Andersson, B., Hall, C., Richards, A.M., Troughton, R., Lainchbury, J., Berry, C., Hogg, K., Norrie, J., Stevenson, K., Brett, M., McMurray, J., Pfeffer, M.A., Swedberg, K., Granger, C.B., Held, P., McMurray, J.J.V., Michelson, E.L., Olofsson, B., Östergren, J., Yusuf, S., Køber, L., Torp-Pedersen, C., Lenzen, M.J., Scholte op Reimer, W.J.M., Boersma, E., Vantrimpont, P.J.M.J., Follath, F., Swedberg, K., Cleland, J., Komajda, M., Gotsman, I., Zwas, D., Planer, D., Azaz-Livshits, T., Admon, D., Lotan, C., Keren, A., Grigorian-Shamagian, L., Varela-Roman, A., Mazón-Ramos, P., Rigeiro-Veloso, P., Bandin-Dieguez, M.A., Gonzalez-Juanatey, J.R., Guazzi, M., Myers, J., Arena, R., McAlister, F.A., Ezekowitz, J., Armstrong, P.W., Cujec, Bibiana, Paterson, Ian, Cowie, M.R., Wood, D.A., Coats, A.J.S., Thompson, S.G., Suresh, V., Poole-Wilson, P.A., Sutton, G.C., Martínez-Sellés, M., Robles, J.A.G., Prieto, L., Muñoa, M.D., Frades, E., Díaz-Castro, O., Almendral, J., Tarantini, L., Faggiano, P., Senni, M., Lucci, D., Bertoli, D., Porcu, M., Opasich, C., Tavazzi, L., Maggioni, A.P., Kirk, V., Bay, M., Parner, J., Krogsgaard, K., Herzog, T.M., Boesgaard, S., Hassager, C., Nielsen, O.W., Aldershvile, J., Nielsen, H., Kober, L., Macín, S.M., Perna, E.R., Cimbaro Canella, J.P., Alvarenga, P., Pantich, R., Ríos, N., Farias, E.F., Badaracco, J.R., Madsen, B.K., Hansen, J.F., Stokholm, K.H., Brons, J., Husum, D., Mortensen, L.S., Bayes-Genis, A., Vazquez, R., Puig, T., Fernandez-Palomeque, C., Bardají, A., Pascual-Figal, D., Ordoñez-Llanos, J., Valdes, M., Gabarrus, A., Pavon, R., Pastor, L., Gonzalez-Juanatey, J.R., Almendral, J., Fiol, M., Nieto, V., Macaya, C., Cinca, J., Cygankiewitz, I., Bayes de Luna, A., Newton, J.D., Blackledge, H.M., Squire, I.B., Wright, S.P., Whalley, G.A., Doughty, R.N., Kerzner, R., Gage, B.F., Freedland, K.E., Rich, M.W., Huynh, B.C., Rovner, A., Freedland, K.E., Carney, R.M., Rich, M.W., Taffet, G.E., Teasdale, T.A., Bleyer, A.J., Kutka, N.J., Luchi, R.J., Tribouilloy, C., Rusinaru, D., Mahjoub, H., Soulière, V., Lévy, F., Peltier, M., Tsutsui, H., Tsuchihashi, M., Takeshita, A., MacCarthy, P.A., Kearney, M.T., Nolan, J., Lee, A.J., Prescott, R.J., Shah, A.M., Brooksby, W.P., Fox, K.A.A., Varela-Roman, A., Gonzalez-Juanatey, J.R., Basante, P., Trillo, R., Garcia-Seara, J., Martinez-Sande, J.L., and Gude, F.

Published
2015
Full Text
View/download PDF

18. Randomized Trials Fit for the 21st Century. A Joint Opinion from the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation

Author

Bowman, L, Weidinger, F, Albert, MA, Fry, ETA, Pinto, FJ, Achenbach, S, Casadei, B, Collins, R, Devereaux, PJ, Douglas, PS, Frobert, O, Goto, S, Grines, C, Harrington, RA, Haynes, R, Hochman, JS, James, S, Kirchhof, P, Komajda, M, Lam, CSP, Landray, M, Maggioni, A, McMurray, J, Medhurst, N, Mehran, R, Neal, B ; https://orcid.org/0000-0002-0490-7465, Rydén, L, Thiele, H, Van Gelder, I, Wallentin, L, Yusuf, S, Zannad, F, Bowman, L, Weidinger, F, Albert, MA, Fry, ETA, Pinto, FJ, Achenbach, S, Casadei, B, Collins, R, Devereaux, PJ, Douglas, PS, Frobert, O, Goto, S, Grines, C, Harrington, RA, Haynes, R, Hochman, JS, James, S, Kirchhof, P, Komajda, M, Lam, CSP, Landray, M, Maggioni, A, McMurray, J, Medhurst, N, Mehran, R, Neal, B ; https://orcid.org/0000-0002-0490-7465, Rydén, L, Thiele, H, Van Gelder, I, Wallentin, L, Yusuf, S, and Zannad, F

Published
2022

19. Identification par étude d’association génome entier (GWAS) de deux nouveaux loci impliqués dans l’insuffisance cardiaque par cardiomyopathie dilatée en 3p25.1 et 22q11.23

Author

Garnier, S, Harakalova, M, Weiss, S, Mokry, M, Isnard, R, Duboscq-Bidot, L, Komajda, M, Cambien, F, Deleuze, J-F, Dörr, M, Asselbergs F, W, Villard, E, Trégouët, D-A, Charron, P, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Utrecht University [Utrecht], Universität Greifswald - University of Greifswald, Sorbonne Université (SU), Centre National de Recherche en Génomique Humaine (CNRGH), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratory of Excellence GENMED [Paris] (Medical Genomics), University of Medicine Greifswald, German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), and SFGH

Subjects
[SDV]Life Sciences [q-bio]
Published
2022

20. Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)

Author

Wong, Chih M., Hawkins, Nathaniel M., Petrie, Mark C., Jhund, Pardeep S., Gardner, Roy S., Ariti, Cono A., Poppe, Katrina K., Earle, Nikki, Whalley, Gillian A., Squire, Iain B., Doughty, Robert N., McMurray, John J.V., Berry, C., Doughty, R., Granger, C., Køber, L., Massie, B., McAlister, F., McMurray, J., Pocock, S., Poppe, K., Swedberg, K., Somaratne, J., Whalley, G., Ahmed, A., Andersson, B., Bayes-Genis, A., Berry, C., Cowie, M., Cubbon, R., Doughty, R., Ezekowitz, J., Gonzalez-Juanatey, J., Gorini, M., Gotsman, I., Grigorian-Shamagian, L., Guazzi, M., Kearney, M., Køber, L., Komajda, M., di Lenarda, A., Lenzen, M., Lucci, D., Macín, S., Madsen, B., Maggioni, A., Martínez-Sellés, M., McAlister, F., Oliva, F., Poppe, K., Rich, M., Richards, M., Senni, M., Squire, I., Taffet, G., Tarantini, L., Tribouilloy, C., Troughton, R., Tsutsui, H., Whalley, G., Doughty, R., Earle, N., Gamble, G.D., Poppe, K., Whalley, G., Ariti, C., Dobson, J., Pocock, S., Poppe, K., Doughty, R.N., Whalley, G., Andersson, B., Hall, C., Richards, A.M., Troughton, R., Lainchbury, J., Berry, C., Hogg, K., Norrie, J., Stevenson, K., Brett, M., McMurray, J., Pfeffer, M.A., Swedberg, K., Granger, C.B., Held, P., McMurray, J.J.V., Michelson, E.L., Olofsson, B., Östergren, J., Yusuf, S., Køber, L., Torp-Pedersen, C., Ahmed, Ali, Lenzen, M.J., Scholte op Reimer, W.J.M., Boersma, E., Vantrimpont, P.J.M.J., Follath, F., Swedberg, K., Cleland, J., Komajda, M., Gotsman, I., Zwas, D., Planer, D., Azaz-Livshits, T., Admon, D., Lotan, C., Keren, A., Grigorian-Shamagian, L., Varela-Roman, A., Mazón-Ramos, P., Rigeiro-Veloso, P., Bandin-Dieguez, M.A., Gonzalez-Juanatey, J.R., Guazzi, M., Myers, J., Arena, R., McAlister, F.A., Ezekowitz, J., Armstrong, P.W., Cujec, Bibiana, Paterson, Ian, Cowie, M.R., Wood, D.A., Coats, A.J.S., Thompson, S.G., Suresh, V., Poole-Wilson, P.A., Sutton, G.C., Martínez-Sellés, M., Robles, J.A.G., Prieto, L., Muñoa, M.D., Frades, E., Díaz-Castro, O., Almendral, J., Tarantini, L., Faggiano, P., Senni, M., Lucci, D., Bertoli, D., Porcu, M., Opasich, C., Tavazzi, L., Maggioni, A.P., Kirk, V., Bay, M., Parner, J., Krogsgaard, K., Herzog, T.M., Boesgaard, S., Hassager, C., Nielsen, O.W., Aldershvile, J., Nielsen, H., Kober, L., Macín, S.M., Perna, E.R., Cimbaro Canella, J.P., Alvarenga, P., Pantich, R., Ríos, N., Farias, E.F., Badaracco, J.R., Madsen, B.K., Hansen, J.F., Stokholm, K.H., Brons, J., Husum, D., Mortensen, L.S., Bayes-Genis, A., Vazquez, R., Puig, T., Fernandez-Palomeque, C., Bardají, A., Pascual-Figal, D., Ordoñez-Llanos, J., Valdes, M., Gabarrus, A., Pavon, R., Pastor, L., Gonzalez-Juanatey, J.R., Almendral, J., Fiol, M., Nieto, V., Macaya, C., Cinca, J., Bayes de Luna, A., Newton, J.D., Blackledge, H.M., Squire, I.B., Wright, S.P., Whalley, G.A., Doughty, R.N., Kerzner, R., Gage, B.F., Freedland, K.E., Rich, M.W., Huynh, B.C., Rovner, A, Freedland, KE, Carney, RM, Rich, MW, Taffet, GE, Teasdale, T.A., Bleyer, A.J., Kutka, N.J., Luchi, R.J., Tribouilloy, C., Rusinaru, D., Mahjoub, H., Soulière, V., Lévy, F., Peltier, M., Tsutsui, H., Tsuchihashi, M., Takeshita, A., MacCarthy, P.A., Kearney, M.T., Nolan, J., Lee, A.J., Prescott, R.J., Shah, A.M., Brooksby, W.P., Fox, K.A.A., Varela-Roman, A., Gonzalez-Juanatey, J.R., Basante, P., Trillo, R., Garcia-Seara, J., Martinez-Sande, J.L., and Gude, F.

Published
2014
Full Text
View/download PDF

22. Factors associated with one-year mortality in a monocentric cohort of hospitalized heart failure patients in Paris (Ile de France). Insight from SNDS data base.

Author

Abassade, P., Fleury, L., Audrey, F., Chatellier, G., Sacco, E., Beaussier, H., Komajda, M., and Cador, R.

Abstract

The rate of one-year mortality in congestive heart failure (CHF) is high. Several reversible factors could be identified in analysis of observational studies using follow up data. Analysis of factors associated with mortality at one year in a cohort of hospitalized patients for congestive heart failure in Saint Joseph Hospital (SHJ), using the SNDS data base (National data base). From September 2016 to September 2018 all patients hospitalized for CHF in SJH were included. CHF was assessed by ESC criteria. Two groups were built, dead (D) or alive (A). Clinical and biological data, collected from the electronic health record, and follow up data, using SNDS data base, were compared between the two groups. Six hundred and fifteen patients were included. Univariate analysis showed significant differences between the two groups: In the group D, population was older (82.5 ± 9.0 vs 77.5 ± 11.3 years, P < 0.0001), the mean Ejection Fraction was higher (47.7 ± 14.4 vs 44.7 ± 15.1%, P = 0.04), median BNP level at discharge higher (586.0 vs 318,0 P < 0.0001), mean creatinin level higher (147 ± 56 vs 130 ± 63 μmoles/l, P = 0.0006), mean Sodium level lower (135.1 ± 4.2 vs 136.4 ± 4.0 mmoles/l, P = 0.0024), mean hemoglobin lower (11.6 ± 1.6 vs 12.5 ± 1.8 g/dl, P < 0.0001). The rates of conversion enzyme inhibitor or angiotensin receptor blocker (EIC/ARB) consumption was lower (52.6 vs 67.8%, P = 0.0024), beta blocker lower (59.8 vs 72.5%, P = 0.0076), oral direct anticoagulant (ODA) lower (22.3 vs 37.7%, P = 0.0019). In multivariate analysis using Cox model, inclusion in PRADO program (support program for returning home) showed no difference (HR = 0.88 IC95% [0.60; 1.30] P = 0.53). The significate data were, at discharge, Creatinin >100 μmoles/l (HR = 1.76 [1.06; 2.90] P = 0.02), Sodium level > 135 mmoles/l (HR = 0.68 [0.46; 0.99], P = 0.04), Hemoglobin level > 12 g/dl (HR = 0.62 [0.41; 0.93], P = 0.01), and consumption of ODA (HR = 0.57 [0.35; 0.91], P = 0.018), and EIC/ARB (HR = 0.49 [0.31; 0.79], P = 0.003) (Figure 1). Our study confirmed that the CHF population had a poor prognosis despite health care policy and programs. The main factors of poor prognosis are biological data at discharge, reflecting the severity of CHF. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

23. Factors associated with re-hospitalization at one-year for any reason, in a monocentric cohort of hospitalized heart failure patients in Paris (Île-de-France). Analysis of data from SNDS database.

Author

Abassade, P., Fleury, L., Audrey, F., Chatellier, G., Sacco, E., Beaussier, H., Komajda, M., and Cador, R.

Abstract

Congestive heart failure (CHF) is associated with prolonged and recurrent hospitalizations for CHF and for other reasons, since comorbidities are frequently associated. Analysis of factors associated with re-hospitalization for any reason (CHF and others reasons) at one year in a cohort of hospitalized patients for congestive heart failure in Saint Joseph Hospital (SHJ), using the SNDS data base (National database). From September 2016 to September 2018 all patients hospitalized for CHF in SJH were included. CHF was assessed by ESC criteria. Two groups were built: Re-hospitalization for any reason (H), no–rehospitalization (NH). Clinical and biological data, collected from the electronic health record, and follow up data, using SNDS data base, were compared between the two groups. Six hundred and fifteen patients were included. Univariate analysis showed significant differences between the two groups: In the group H (n = 431, 70.08%), the number of male was higher (57.5 vs 43.4%, OR 1.76 [95% CI] [1.24; 2.50] P = 0.001). The number of people older than 81 years was lower (45.0% vs 54.3%, OR 0.69 [0.49; 0.97] P = 0.03). The mean LV Ejection fraction (EF) was higher (46.0 ± 14.8% vs 43.5 ± 15.5%, P = 0.05). Cancer was more frequent (19.2% vs 10.3%, OR 2.07 [1.22; 3.53], P = 0.006). At discharge, mean Hemoglobin was lower (12.2 ± 1.8 vs 12.6 ± 1.8, P = 0.009). In the H group were more prescribed loop diuretics (95.1% vs 88.0%, OR 2.65 [1.42; 4.95], P = 0.001). The median number of consultation with general practitioner is higher (12 [8; 17] vs 9 [6; 14], P < 0.0001). Mortality rate is higher (20.8% vs 11.9%, OR 1.94 [1.18; 3.21], P = 0.008). Multivariate analysis showed that male gender (HR 1.47 [1.19; 1.82], P = 0.0003), age lower than 81 years (HR 0.72 [0.59; 0.88], P = 0.001), EF > 50% (HR 1.63[1.23; 2.16], P = 0.0007), cancer disease (HR = 1.46, [1.14; 1.86], P = 0.002) loop diuretics prescription (HR 1.78 [1.14; 2.77], P = 0.01), were significantly related with rehospitalization for any reasons. Our study confirmed that the CHF population had a very frequent re-hospitalization for any reason, reflecting frailty and comorbidities. The main factors related are male gender, age lower than 81 years, cancer, preserved EF. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

24. Follow-up at one year in a monocentric cohort of hospitalized heart failure patients in Paris (Île-de-France). Factors associated with re-hospitalization for heart failure, insight from SNDS database.

Author

Abassade, P., Fleury, L., Audrey, F., Chatellier, G., Sacco, E., Beaussier, H., Komajda, M., and Cador, R.

Abstract

Congestive heart failure (CHF) is associated with prolonged and recurrent hospitalizations, the prognosis remains poor. Analysis of follow up data could identify related factors. Analysis of factors associated with re-hospitalization for CHF, at one year in a cohort of hospitalized patients for congestive heart failure in Saint Joseph Hospital (SHJ), using the SNDS database (National data base). From September 2016 to September 2018 all patients hospitalized for CHF in SJH were included. CHF was assessed by ESC criteria. Two groups were built: Re-hospitalization for CHF (R), no-rehospitalization for CHF (N). Clinical and biological data, collected from the electronic health record, and follow up data, using SNDS database, were compared between the two groups. Six hundred and fifteen patients were included. Univariate analysis showed significant differences between the two groups: In the group R (n = 226, 36.75%), the number of people older than 81 years was lower (42.4% vs 50.9%, OR 0.71 [IC 95%] [0.51; 0.99], P = 0.04). The mean LV Ejection fraction was lower (43.7 ± 15.1 vs 46.2 ± 14.9%, P = 0.03). At discharge, median BNP was higher (387 [199;863] vs 320 [167; 703] ng/ml, P = 0.002), mean creatinin higher (139 ± 61 vs 130 ± 63 μmoles/l, P = 0.007). In the R group were more prescribed converting Enzyme inhibitor or Angiotensin receptor blocker (71.2 vs 61.2%, OR 1.55 [1.09; 2.21], P = 0.001), loop diuretics (98.2 vs 89.9%, OR 6.18 [2.18; 17.54], P = 0.0001), spironolactone/eplerenone (34.9 vs 23.3%, OR 1.76 [1.23; 2.52], P = 0.002), antiplatelet agents (48.6 vs 36.5%, OR 1.65 [1.18; 2.30], P = 0.001). The median number of consultation with general practitioner is higher (12 [7; 17] vs 11 [7; 15], P = 0.03). Mortality rate is higher but not significate (22.1 vs 15.9%, OR 1.50 [0.99; 2.27], P = 0.06). Multivariate analysis showed that creatinin < 100 μmoles/l at discharge (HR 1.39 [1.02; 1.89], P = 0.03), loop diuretics prescription (HR 4.02 [1.046; 11.03], P = 0.006), and antiplatelet agents (HR 1.50 [1.11; 2.01], P = 0.007) were significantly related with rehospitalization for CHF. Our study confirmed that the CHF population had a frequent re-hospitalization for CHF despite health care policy and programs. The main factors related are biological data at discharge, and healthcare consumption during follow up. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

25. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

Author

Verma, Subodh, primary, Dhingra, Nitish K, additional, Butler, Javed, additional, Anker, Stefan D, additional, Ferreira, Joao Pedro, additional, Filippatos, Gerasimos, additional, Januzzi, James L, additional, Lam, Carolyn S P, additional, Sattar, Naveed, additional, Peil, Barbara, additional, Nordaby, Matias, additional, Brueckmann, Martina, additional, Pocock, Stuart J, additional, Zannad, Faiez, additional, Packer, Milton, additional, Packer, M, additional, Anker, S, additional, Butler, J, additional, Filippatos, G, additional, Pocock, S, additional, Zannad, F, additional, Ferreira, JP, additional, Brueckmann, M, additional, George, J, additional, Jamal, W, additional, Welty, FK, additional, Palmer, M, additional, Clayton, T, additional, Parhofer, KG, additional, Pedersen, TR, additional, Greenberg, B, additional, Konstam, MA, additional, Lees, KR, additional, Carson, P, additional, Doehner, W, additional, Miller, A, additional, Haas, M, additional, Pehrson, S, additional, Komajda, M, additional, Anand, I, additional, Teerlink, J, additional, Rabinstein, A, additional, Steiner, T, additional, Kamel, H, additional, Tsivgoulis, G, additional, Lewis, J, additional, Freston, J, additional, Kaplowitz, N, additional, Mann, J, additional, Petrie, J, additional, Perrone, S, additional, Nicholls, S, additional, Janssens, S, additional, Bocchi, E, additional, Giannetti, N, additional, Verma, S, additional, Zhang, J, additional, Spinar, J, additional, Seronde, M-F, additional, Boehm, M, additional, Merkely, B, additional, Chopra, V, additional, Senni, M, additional, Taddi, S, additional, Tsutsui, H, additional, Choi, D-J, additional, Chuquiure, E, additional, La Rocca, HPB, additional, Ponikowski, P, additional, Juanatey, JRG, additional, Squire, I, additional, Januzzi, J, additional, Pina, I, additional, Bernstein, R, additional, Cheung, A, additional, Green, J, additional, Kaul, S, additional, Lam, C, additional, Lip, G, additional, Marx, N, additional, McCullough, P, additional, Mehta, C, additional, Rosenstock, J, additional, Sattar, N, additional, Scirica, B, additional, Shah, S, additional, Wanner, C, additional, Aizenberg, D, additional, Cartasegna, L, additional, Colombo Berra, F, additional, Colombo, H, additional, Fernandez Moutin, M, additional, Glenny, J, additional, Alvarez Lorio, C, additional, Anauch, D, additional, Campos, R, additional, Facta, A, additional, Fernandez, A, additional, Ahuad Guerrero, R, additional, Lobo Márquez, L, additional, Leon de la Fuente, RA, additional, Mansilla, M, additional, Hominal, M, additional, Hasbani, E, additional, Najenson, M, additional, Moises Azize, G, additional, Luquez, H, additional, Guzman, L, additional, Sessa, H, additional, Amuchástegui, M, additional, Salomone, O, additional, Perna, E, additional, Piskorz, D, additional, Sicer, M, additional, Perez de Arenaza, D, additional, Zaidman, C, additional, Nani, S, additional, Poy, C, additional, Resk, J, additional, Villarreal, R, additional, Majul, C, additional, Smith Casabella, T, additional, Sassone, S, additional, Liberman, A, additional, Carnero, G, additional, Caccavo, A, additional, Berli, M, additional, Budassi, N, additional, Bono, J, additional, Alvarisqueta, A, additional, Amerena, J, additional, Kostner, K, additional, Hamilton, A, additional, Begg, A, additional, Beltrame, J, additional, Colquhoun, D, additional, Gordon, G, additional, Sverdlov, A, additional, Vaddadi, G, additional, Wong, J, additional, Coller, J, additional, Prior, D, additional, Friart, A, additional, Leone, A, additional, Vervoort, G, additional, Timmermans, P, additional, Troisfontaines, P, additional, Franssen, C, additional, Sarens, T, additional, Vandekerckhove, H, additional, Van De Borne, P, additional, Chenot, F, additional, De Sutter, J, additional, De Vuyst, E, additional, Debonnaire, P, additional, Dupont, M, additional, Pereira Dutra, O, additional, Canani, LH, additional, Vieira Moreira, MdC, additional, de Souza, W, additional, Backes, LM, additional, Maia, L, additional, De Souza Paolino, B, additional, Manenti, ER, additional, Saporito, W, additional, Villaça Guimarães Filho, F, additional, Franco Hirakawa, T, additional, Saliba, LA, additional, Neuenschwander, FC, additional, de Freitas Zerbini, CA, additional, Gonçalves, G, additional, Gonçalves Mello, Y, additional, Ascenção de Souza, J, additional, Beck da Silva Neto, L, additional, Bocchi, EA, additional, Da Silveira, J, additional, de Moura Xavier Moraes Junior, JB, additional, de Souza Neto, JD, additional, Hernandes, M, additional, Finimundi, HC, additional, Sampaio, CR, additional, Vasconcellos, E, additional, Neves Mancuso, FJ, additional, Noya Rabelo, MM, additional, Rodrigues Bacci, M, additional, Santos, F, additional, Vidotti, M, additional, Simões, MV, additional, Gomes, FL, additional, Vieira Nascimento, C, additional, Precoma, D, additional, Helfenstein Fonseca, FA, additional, Ribas Fortes, JA, additional, Leães, PE, additional, Campos de Albuquerque, D, additional, Kerr Saraiva, JF, additional, Rassi, S, additional, Alves da Costa, FA, additional, Reis, G, additional, Zieroth, S, additional, Dion, D, additional, Savard, D, additional, Bourgeois, R, additional, Constance, C, additional, Anderson, K, additional, Leblanc, M-H, additional, Yung, D, additional, Swiggum, E, additional, Pliamm, L, additional, Pesant, Y, additional, Tyrrell, B, additional, Huynh, T, additional, Spiegelman, J, additional, Lavoie, J-P, additional, Hartleib, M, additional, Bhargava, R, additional, Straatman, L, additional, Virani, S, additional, Costa-Vitali, A, additional, Hill, L, additional, Heffernan, M, additional, Khaykin, Y, additional, Ricci, J, additional, Senaratne, M, additional, Zhai, A, additional, Lubelsky, B, additional, Toma, M, additional, Yao, L, additional, McKelvie, R, additional, Noronha, L, additional, Babapulle, M, additional, Pandey, A, additional, Curnew, G, additional, Lavoie, A, additional, Berlingieri, J, additional, Kouz, S, additional, Lonn, E, additional, Chehayeb, R, additional, Zheng, Y, additional, Sun, Y, additional, Cui, H, additional, Fan, Z, additional, Han, X, additional, Jiang, X, additional, Tang, Q, additional, Zhou, J, additional, Zheng, Z, additional, Zhang, X, additional, Zhang, N, additional, Zhang, Y, additional, Shen, A, additional, Yu, J, additional, Ye, J, additional, Yao, Y, additional, Yan, J, additional, Xu, X, additional, Wang, Z, additional, Ma, J, additional, Li, Y, additional, Li, S, additional, Lu, S, additional, Kong, X, additional, Song, Y, additional, Yang, G, additional, Yao, Z, additional, Pan, Y, additional, Guo, X, additional, Sun, Z, additional, Dong, Y, additional, Zhu, J, additional, Peng, D, additional, Yuan, Z, additional, Lin, J, additional, Yin, Y, additional, Jerabek, O, additional, Burianova, H, additional, Fiala, T, additional, Hubac, J, additional, Ludka, O, additional, Monhart, Z, additional, Vodnansky, P, additional, Zeman, K, additional, Foldyna, D, additional, Krupicka, J, additional, Podpera, I, additional, Busak, L, additional, Radvan, M, additional, Vomacka, Z, additional, Prosecky, R, additional, Cifkova, R, additional, Durdil, V, additional, Vesely, J, additional, Vaclavik, J, additional, Cervinka, P, additional, Linhart, A, additional, Brabec, T, additional, Miklik, R, additional, Bourhaial, H, additional, Olbrich, H-G, additional, Genth-Zotz, S, additional, Kemala, E, additional, Lemke, B, additional, Böhm, M, additional, Schellong, S, additional, Rieker, W, additional, Heitzer, T, additional, Ince, H, additional, Faghih, M, additional, Birkenfeld, A, additional, Begemann, A, additional, Ghanem, A, additional, Ujeyl, A, additional, von Haehling, S, additional, Dorsel, T, additional, Bauersachs, J, additional, Prull, M, additional, Weidemann, F, additional, Darius, H, additional, Nickenig, G, additional, Wilke, A, additional, Sauter, J, additional, Rauch-Kroehnert, U, additional, Frey, N, additional, Schulze, CP, additional, König, W, additional, Maier, L, additional, Menzel, F, additional, Proskynitopoulos, N, additional, Ebert, H-H, additional, Sarnighausen, H-E, additional, Düngen, H-D, additional, Licka, M, additional, Stellbrink, C, additional, Winkelmann, B, additional, Menck, N, additional, López-Sendón, JL, additional, de la Fuente Galán, L, additional, Delgado Jiménez, JF, additional, Manito Lorite, N, additional, Pérez de Juan Romero, M, additional, Galve Basilio, E, additional, Cereto Castro, F, additional, González Juanatey, JR, additional, Gómez, JJ, additional, Sanmartín Fernández, M, additional, Garcia-Moll Marimon, X, additional, Pascual Figal, D, additional, Bover Freire, R, additional, Bonnefoy Cudraz, E, additional, Jobbe Duval, A, additional, Tomasevic, D, additional, Habib, G, additional, Isnard, R, additional, Picard, F, additional, Khanoyan, P, additional, Dubois-Rande, J-L, additional, Galinier, M, additional, Roubille, F, additional, Alexandre, J, additional, Babuty, D, additional, Delarche, N, additional, Berneau, J-B, additional, Girerd, N, additional, Saxena, M, additional, Rosano, G, additional, Yousef, Z, additional, Clifford, C, additional, Arden, C, additional, Bakhai, A, additional, Boos, C, additional, Jenkins, G, additional, Travill, C, additional, Price, D, additional, Koenyves, L, additional, Lakatos, F, additional, Matoltsy, A, additional, Noori, E, additional, Zilahi, Z, additional, Andrassy, P, additional, Kancz, S, additional, Simon, G, additional, Sydo, T, additional, Vorobcsuk, A, additional, Kiss, RG, additional, Toth, K, additional, Szakal, I, additional, Nagy, L, additional, Barany, T, additional, Nagy, A, additional, Szolnoki, E, additional, Chopra, VK, additional, Mandal, S, additional, Rastogi, V, additional, Shah, B, additional, Mullasari, A, additional, Shankar, J, additional, Mehta, V, additional, Oomman, A, additional, Kaul, U, additional, Komarlu, S, additional, Kahali, D, additional, Bhagwat, A, additional, Vijan, V, additional, Ghaisas, NK, additional, Mehta, A, additional, Kashyap, J, additional, Kothari, Y, additional, TaddeI, S, additional, Scherillo, M, additional, Zacà, V, additional, Genovese, S, additional, Salvioni, A, additional, Fucili, A, additional, Fedele, F, additional, Cosmi, F, additional, Volpe, M, additional, Mazzone, C, additional, Esposito, G, additional, Doi, M, additional, Yamamoto, H, additional, Sakagami, S, additional, Oishi, S, additional, Yasaka, Y, additional, Tsuboi, H, additional, Fujino, Y, additional, Matsuoka, S, additional, Watanabe, Y, additional, Himi, T, additional, Ide, T, additional, Ichikawa, M, additional, Kijima, Y, additional, Koga, T, additional, Yuda, S, additional, Fukui, K, additional, Kubota, T, additional, Manita, M, additional, Fujinaga, H, additional, Matsumura, T, additional, Fukumoto, Y, additional, Kato, R, additional, Kawai, Y, additional, Hiasa, G, additional, Kazatani, Y, additional, Mori, M, additional, Ogimoto, A, additional, Inoko, M, additional, Oguri, M, additional, Kinoshita, M, additional, Okuhara, K, additional, Watanabe, N, additional, Ono, Y, additional, Otomo, K, additional, Sato, Y, additional, Matsunaga, T, additional, Takaishi, A, additional, Miyagi, N, additional, Uehara, H, additional, Takaishi, H, additional, Urata, H, additional, Kataoka, T, additional, Matsubara, H, additional, Matsumoto, T, additional, Suzuki, T, additional, Takahashi, N, additional, Imamaki, M, additional, Yoshitama, T, additional, Saito, T, additional, Sekino, H, additional, Furutani, Y, additional, Koda, M, additional, Shinozaki, T, additional, Hirabayashi, K, additional, Tsunoda, R, additional, Yonezawa, K, additional, Hori, H, additional, Yagi, M, additional, Arikawa, M, additional, Hashizume, T, additional, Ishiki, R, additional, Koizumi, T, additional, Nakayama, K, additional, Taguchi, S, additional, Nanasato, M, additional, Yoshida, Y, additional, Tsujiyama, S, additional, Nakamura, T, additional, Oku, K, additional, Shimizu, M, additional, Suwa, M, additional, Momiyama, Y, additional, Sugiyama, H, additional, Kobayashi, K, additional, Inoue, S, additional, Kadokami, T, additional, Maeno, K, additional, Kawamitsu, K, additional, Maruyama, Y, additional, Nakata, A, additional, Shibata, T, additional, Wada, A, additional, Cho, H-J, additional, Na, JO, additional, Yoo, B-S, additional, Choi, J-O, additional, Hong, SK, additional, Shin, J-H, additional, Cho, M-C, additional, Han, SH, additional, Jeong, J-O, additional, Kim, J-J, additional, Kang, SM, additional, Kim, D-S, additional, Kim, MH, additional, Llamas Esperon, G, additional, Illescas Díaz, J, additional, Fajardo Campos, P, additional, Almeida Alvarado, J, additional, Bazzoni Ruiz, A, additional, Echeverri Rico, J, additional, Lopez Alcocer, I, additional, Valle Molina, L, additional, Hernandez Herrera, C, additional, Calvo Vargas, C, additional, Padilla Padilla, FG, additional, Rodriguez Briones, I, additional, Chuquiure Valenzuela, EJJR, additional, Aguilera Real, ME, additional, Carrillo Calvillo, J, additional, Alpizar Salazar, M, additional, Cervantes Escárcega, JL, additional, Velasco Sanchez, R, additional, Al - Windy, N, additional, van Heerebeek, L, additional, Bellersen, L, additional, Brunner-La Rocca, H-P, additional, Post, J, additional, Linssen, GCM, additional, van de Wetering, M, additional, Peters, R, additional, van Stralen, R, additional, Groutars, R, additional, Smits, P, additional, Yilmaz, A, additional, Kok, WEM, additional, Van der Meer, P, additional, Dijkmans, P, additional, Troquay, R, additional, van Alem, AP, additional, Van de Wal, R, additional, Handoko, L, additional, Westendorp, ICD, additional, van Bergen, PFMM, additional, Rensing, BJWM, additional, Hoogslag, P, additional, Kietselaer, B, additional, Kragten, JA, additional, den Hartog, FR, additional, Alings, A, additional, Danilowicz-Szymanowicz, L, additional, Raczak, G, additional, Piesiewicz, W, additional, Zmuda, W, additional, Kus, W, additional, Podolec, P, additional, Musial, W, additional, Drelich, G, additional, Kania, G, additional, Miekus, P, additional, Mazur, S, additional, Janik, A, additional, Spyra, J, additional, Peruga, J, additional, Balsam, P, additional, Krakowiak, B, additional, Szachniewicz, J, additional, Ginel, M, additional, Grzybowski, J, additional, Chrustowski, W, additional, Wojewoda, P, additional, Kalinka, A, additional, Zurakowski, A, additional, Koc, R, additional, Debinski, M, additional, Fil, W, additional, Kujawiak, M, additional, Forys, J, additional, Kasprzak, M, additional, Krol, M, additional, Michalski, P, additional, Mirek-Bryniarska, E, additional, Radwan, K, additional, Skonieczny, G, additional, Stania, K, additional, Skoczylas, G, additional, Madej, A, additional, Jurowiecki, J, additional, Firek, B, additional, Wozakowska-Kaplon, B, additional, Cymerman, K, additional, Neutel, J, additional, Adams, K, additional, Balfour, P, additional, Deswal, A, additional, Djamson, A, additional, Duncan, P, additional, Hong, M, additional, Murray, C, additional, Rinde-Hoffman, D, additional, Woodhouse, S, additional, MacNevin, R, additional, Rama, B, additional, Broome-Webster, C, additional, Kindsvater, S, additional, Abramov, D, additional, Barettella, M, additional, Pinney, S, additional, Herre, J, additional, Cohen, A, additional, Vora, K, additional, Challappa, K, additional, West, S, additional, Baum, S, additional, Cox, J, additional, Jani, S, additional, Karim, A, additional, Akhtar, A, additional, Quintana, O, additional, Paukman, L, additional, Goldberg, R, additional, Bhatti, Z, additional, Budoff, M, additional, Bush, E, additional, Potler, A, additional, Delgado, R, additional, Ellis, B, additional, Dy, J, additional, Fialkow, J, additional, Sangrigoli, R, additional, Ferdinand, K, additional, East, C, additional, Falkowski, S, additional, Donahoe, S, additional, Ebrahimi, R, additional, Kline, G, additional, Harris, B, additional, Khouzam, R, additional, Jaffrani, N, additional, Jarmukli, N, additional, Kazemi, N, additional, Koren, M, additional, Friedman, K, additional, Herzog, W, additional, Silva Enciso, J, additional, Cheung, D, additional, Grover-McKay, M, additional, Hauptman, P, additional, Mikhalkova, D, additional, Hegde, V, additional, Hodsden, J, additional, Khouri, S, additional, McGrew, F, additional, Littlefield, R, additional, Bradley, P, additional, McLaurin, B, additional, Lupovitch, S, additional, Labin, I, additional, Rao, V, additional, Leithe, M, additional, Lesko, M, additional, Lewis, N, additional, Lombardo, D, additional, Mahal, S, additional, Malhotra, V, additional, Dauber, I, additional, Banerjee, A, additional, Needell, J, additional, Miller, G, additional, Paladino, L, additional, Munuswamy, K, additional, Nanna, M, additional, McMillan, E, additional, Mumma, M, additional, Napoli, M, additional, Nelson, W, additional, O'Brien, T, additional, Adlakha, A, additional, Onwuanyi, A, additional, Serota, H, additional, Schmedtje, J, additional, Paraschos, A, additional, Potu, R, additional, Sai-Sudhakar, C, additional, Saltzberg, M, additional, Sauer, A, additional, Shah, P, additional, Skopicki, H, additional, Bui, H, additional, Carr, K, additional, Stevens, G, additional, Tahirkheli, N, additional, Tallaj, J, additional, Yousuf, K, additional, Trichon, B, additional, Welker, J, additional, Tolerico, P, additional, Vest, A, additional, Vivo, R, additional, Wang, X, additional, Abadier, R, additional, Dunlap, S, additional, Weintraub, N, additional, Malik, A, additional, Kotha, P, additional, Zaha, V, additional, Kim, G, additional, Uriel, N, additional, Greene, T, additional, Salacata, A, additional, Arora, R, additional, Gazmuri, R, additional, Kobayashi, J, additional, Iteld, B, additional, Vijayakrishnan, R, additional, Dab, R, additional, Mirza, Z, additional, Marques, V, additional, Nallasivan, M, additional, Bensimhon, D, additional, Peart, B, additional, Saint-Jacques, H, additional, Barringhaus, K, additional, Contreras, J, additional, Gupta, A, additional, Koneru, S, additional, and Nguyen, V, additional

Published
2022
Full Text
View/download PDF

26. Detection of two new DNA/chromatin regions increasing DCM risk

Author

Garnier, Sophie, Harakalova, M, Weiss, S, Mokry, M, Isnard, R, Duboscq-Bidot, L, Komajda, M, Dörr, M, Asselbergs F, W, Deleuze, J-F, Villard, E, Cambien, F, Trégouët, D-A, Charron, P, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Utrecht University [Utrecht], Universität Greifswald - University of Greifswald, Sorbonne Université (SU), University of Medicine Greifswald, Centre National de Recherche en Génomique Humaine (CNRGH), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratory of Excellence GENMED [Paris] (Medical Genomics), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience

Published
2021

29. Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial

Author

Packer, M, Butler, J, Filippatos, G, Jamal, W, Salsali, A, Schnee, J, Kimura, K, Zeller, C, George, J, Brueckmann, M, Anker, S, Zannad, F, Perrone, S, Nicholls, S, Janssens, S, Bocchi, E, Giannetti, N, Verma, S, Jian, Z, Spinar, J, Seronde, M, Bohm, M, Merkely, B, Chopra, V, Senni, M, Taddei, S, Tsutsui, H, Choi, D, Chuquiure, E, La Rocca, H, Ponikowski, P, Juanatey, J, Squire, I, Januzzi, J, Pina, I, Pocock, S, Carson, P, Doehner, W, Miller, A, Haas, M, Pehrson, S, Komajda, M, Anand, I, Teerlink, J, Rabinstein, A, Steiner, T, Kamel, H, Tsivgoulis, G, Lewis, J, Freston, J, Kaplowitz, N, Mann, J, Petrie, M, Bernstein, R, Cheung, A, Green, J, Kaul, S, Ping, C, Lip, G, Marx, N, Mccullough, P, Mehta, C, Rosenstock, J, Sattar, N, Scirica, B, Wanner, C, Welty, F, Parhofer, K, Clayton, T, Pedersen, T, Lees, K, Konstam, M, Greenberg, B, Palmer, M, Packer M., Butler J., Filippatos G. S., Jamal W., Salsali A., Schnee J., Kimura K., Zeller C., George J., Brueckmann M., Anker S. D., Zannad F., Perrone S., Nicholls S., Janssens S., Bocchi E., Giannetti N., Verma S., Jian Z., Spinar J., Seronde M. -F., Bohm M., Merkely B., Chopra V., Senni M., Taddei S., Tsutsui H., Choi D. -J., Chuquiure E., La Rocca H. P. B., Ponikowski P., Juanatey J. R. G., Squire I., Januzzi J., Pina I., Pocock S. J., Carson P., Doehner W., Miller A., Haas M., Pehrson S., Komajda M., Anand I., Teerlink J., Rabinstein A., Steiner T., Kamel H., Tsivgoulis G., Lewis J., Freston J., Kaplowitz N., Mann J., Petrie M., Bernstein R., Cheung A., Green J., Kaul S., Ping C. L. S., Lip G., Marx N., McCullough P., Mehta C., Rosenstock J., Sattar N., Scirica B., Wanner C., Welty F. K., Parhofer K. G., Clayton T., Pedersen T. R., Lees K. R., Konstam M. A., Greenberg B., Palmer M., Packer, M, Butler, J, Filippatos, G, Jamal, W, Salsali, A, Schnee, J, Kimura, K, Zeller, C, George, J, Brueckmann, M, Anker, S, Zannad, F, Perrone, S, Nicholls, S, Janssens, S, Bocchi, E, Giannetti, N, Verma, S, Jian, Z, Spinar, J, Seronde, M, Bohm, M, Merkely, B, Chopra, V, Senni, M, Taddei, S, Tsutsui, H, Choi, D, Chuquiure, E, La Rocca, H, Ponikowski, P, Juanatey, J, Squire, I, Januzzi, J, Pina, I, Pocock, S, Carson, P, Doehner, W, Miller, A, Haas, M, Pehrson, S, Komajda, M, Anand, I, Teerlink, J, Rabinstein, A, Steiner, T, Kamel, H, Tsivgoulis, G, Lewis, J, Freston, J, Kaplowitz, N, Mann, J, Petrie, M, Bernstein, R, Cheung, A, Green, J, Kaul, S, Ping, C, Lip, G, Marx, N, Mccullough, P, Mehta, C, Rosenstock, J, Sattar, N, Scirica, B, Wanner, C, Welty, F, Parhofer, K, Clayton, T, Pedersen, T, Lees, K, Konstam, M, Greenberg, B, Palmer, M, Packer M., Butler J., Filippatos G. S., Jamal W., Salsali A., Schnee J., Kimura K., Zeller C., George J., Brueckmann M., Anker S. D., Zannad F., Perrone S., Nicholls S., Janssens S., Bocchi E., Giannetti N., Verma S., Jian Z., Spinar J., Seronde M. -F., Bohm M., Merkely B., Chopra V., Senni M., Taddei S., Tsutsui H., Choi D. -J., Chuquiure E., La Rocca H. P. B., Ponikowski P., Juanatey J. R. G., Squire I., Januzzi J., Pina I., Pocock S. J., Carson P., Doehner W., Miller A., Haas M., Pehrson S., Komajda M., Anand I., Teerlink J., Rabinstein A., Steiner T., Kamel H., Tsivgoulis G., Lewis J., Freston J., Kaplowitz N., Mann J., Petrie M., Bernstein R., Cheung A., Green J., Kaul S., Ping C. L. S., Lip G., Marx N., McCullough P., Mehta C., Rosenstock J., Sattar N., Scirica B., Wanner C., Welty F. K., Parhofer K. G., Clayton T., Pedersen T. R., Lees K. R., Konstam M. A., Greenberg B., and Palmer M.

Abstract

Drugs that inhibit the sodium–glucose co-transporter 2 (SGLT2) have been shown to reduce the risk of hospitalizations for heart failure in patients with type 2 diabetes. In populations that largely did not have heart failure at the time of enrolment, empagliflozin, canagliflozin and dapagliflozin decreased the risk of serious new-onset heart failure events by ≈30%. In addition, in the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of both pump failure and sudden deaths, the two most common modes of death among patients with heart failure. In none of the three trials could the benefits of SGLT2 inhibitors on heart failure be explained by the actions of these drugs as diuretics or anti-hyperglycaemic agents. These observations raise the possibility that SGLT2 inhibitors could reduce morbidity and mortality in patients with established heart failure, including those without diabetes. The EMPEROR-Reduced trial is enrolling ≈3600 patients with heart failure and a reduced left ventricular ejection fraction (≤ 40%), half of whom are expected not to have diabetes. Patients are being randomized to placebo or empagliflozin 10 mg daily, which is added to all appropriate treatment with inhibitors of the renin–angiotensin system and neprilysin, beta-blockers and mineralocorticoid receptor antagonists. The primary endpoint is the time-to-first event analysis of the combined risk of cardiovascular death and hospitalization for heart failure, but the trial will also evaluate the effects of empagliflozin on renal function, cardiovascular death, all-cause mortality, and recurrent hospitalization events. By adjusting eligibility based on natriuretic peptide levels to the baseline ejection fraction, the trial will preferentially enrol high-risk patients. A large proportion of the participants is expected to have an ejection fraction < 30%, and the estimated annual event rate is expected to be at least 15%. The EMPEROR-Reduced trial is well-positioned to determine if the addi

Published
2019

30. Evaluation of the effects of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial

Author

Anker, S, Butler, J, Filippatos, G, Jamal, W, Salsali, A, Schnee, J, Kimura, K, Zeller, C, George, J, Brueckmann, M, Zannad, F, Packer, M, Perrone, S, Nicholls, S, Janssens, S, Bocchi, E, Giannetti, N, Verma, S, Jian, Z, Gomez Mesa, J, Spinar, J, Bohm, M, Merkely, B, Chopra, V, Senni, M, Taddi, S, Tsutsui, H, Chuquiure, E, La Rocca, H, Ponikowski, P, Vinereanu, D, Sim, D, Choi, D, Juanatey, J, Squire, I, Januzzi, J, Pina, I, Pocock, S, Carson, P, Doehner, W, Miller, A, Haas, M, Pehrson, S, Komajda, M, Anand, I, Teerlink, J, Rabinstein, A, Steiner, T, Kamel, H, Tsivgoulis, G, Lewis, J, Freston, J, Kaplowitz, N, Mann, J, Petrie, M, Bernstein, R, Cheung, A, Green, J, Kaul, S, Ping, C, Lip, G, Marx, N, Mccullough, P, Mehta, C, Rosenstock, J, Sattar, N, Scirica, B, Wanner, C, Welty, F, Parhofer, K, Clayton, T, Pedersen, T, Lees, K, Konstam, M, Greenberg, B, Palmer, M, Anker S. D., Butler J., Filippatos G. S., Jamal W., Salsali A., Schnee J., Kimura K., Zeller C., George J., Brueckmann M., Zannad F., Packer M., Perrone S., Nicholls S., Janssens S., Bocchi E., Giannetti N., Verma S., Jian Z., Gomez Mesa J. E., Spinar J., Bohm M., Merkely B., Chopra V., Senni M., Taddi S., Tsutsui H., Chuquiure E., La Rocca H. P. B., Ponikowski P., Vinereanu D., Sim D., Choi D. -J., Juanatey J. R. G., Squire I., Januzzi J., Pina I., Pocock S. J., Carson P., Doehner W., Miller A., Haas M., Pehrson S., Komajda M., Anand I., Teerlink J., Rabinstein A., Steiner T., Kamel H., Tsivgoulis G., Lewis J., Freston J., Kaplowitz N., Mann J., Petrie M., Bernstein R., Cheung A., Green J., Kaul S., Ping C. L. S., Lip G., Marx N., McCullough P., Mehta C., Rosenstock J., Sattar N., Scirica B., Wanner C., Welty F. K., Parhofer K. G., Clayton T., Pedersen T. R., Lees K. R., Konstam M. A., Greenberg B., Palmer M., Anker, S, Butler, J, Filippatos, G, Jamal, W, Salsali, A, Schnee, J, Kimura, K, Zeller, C, George, J, Brueckmann, M, Zannad, F, Packer, M, Perrone, S, Nicholls, S, Janssens, S, Bocchi, E, Giannetti, N, Verma, S, Jian, Z, Gomez Mesa, J, Spinar, J, Bohm, M, Merkely, B, Chopra, V, Senni, M, Taddi, S, Tsutsui, H, Chuquiure, E, La Rocca, H, Ponikowski, P, Vinereanu, D, Sim, D, Choi, D, Juanatey, J, Squire, I, Januzzi, J, Pina, I, Pocock, S, Carson, P, Doehner, W, Miller, A, Haas, M, Pehrson, S, Komajda, M, Anand, I, Teerlink, J, Rabinstein, A, Steiner, T, Kamel, H, Tsivgoulis, G, Lewis, J, Freston, J, Kaplowitz, N, Mann, J, Petrie, M, Bernstein, R, Cheung, A, Green, J, Kaul, S, Ping, C, Lip, G, Marx, N, Mccullough, P, Mehta, C, Rosenstock, J, Sattar, N, Scirica, B, Wanner, C, Welty, F, Parhofer, K, Clayton, T, Pedersen, T, Lees, K, Konstam, M, Greenberg, B, Palmer, M, Anker S. D., Butler J., Filippatos G. S., Jamal W., Salsali A., Schnee J., Kimura K., Zeller C., George J., Brueckmann M., Zannad F., Packer M., Perrone S., Nicholls S., Janssens S., Bocchi E., Giannetti N., Verma S., Jian Z., Gomez Mesa J. E., Spinar J., Bohm M., Merkely B., Chopra V., Senni M., Taddi S., Tsutsui H., Chuquiure E., La Rocca H. P. B., Ponikowski P., Vinereanu D., Sim D., Choi D. -J., Juanatey J. R. G., Squire I., Januzzi J., Pina I., Pocock S. J., Carson P., Doehner W., Miller A., Haas M., Pehrson S., Komajda M., Anand I., Teerlink J., Rabinstein A., Steiner T., Kamel H., Tsivgoulis G., Lewis J., Freston J., Kaplowitz N., Mann J., Petrie M., Bernstein R., Cheung A., Green J., Kaul S., Ping C. L. S., Lip G., Marx N., McCullough P., Mehta C., Rosenstock J., Sattar N., Scirica B., Wanner C., Welty F. K., Parhofer K. G., Clayton T., Pedersen T. R., Lees K. R., Konstam M. A., Greenberg B., and Palmer M.

Abstract

Background: The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue accumulation, coronary microcirculatory rarefaction, myocardial fibrosis and vascular stiffness; the resulting impairment of left ventricular and aortic distensibility (especially when accompanied by impaired glomerular function and sodium retention) causes increases in cardiac filling pressures and exertional dyspnoea despite the relative preservation of left ventricular ejection fraction. Independently of their actions on blood glucose, sodium–glucose co-transporter 2 (SGLT2) inhibitors exert a broad range of biological effects (including actions to inhibit cardiac inflammation and fibrosis, antagonize sodium retention and improve glomerular function) that can ameliorate the pathophysiological derangements in HFpEF. Such SGLT2 inhibitors exert favourable effects in experimental models of HFpEF and have been found in large-scale trials to reduce the risk for serious heart failure events in patients with type 2 diabetes, many of whom were retrospectively identified as having HFpEF. Study design: The EMPEROR-Preserved Trial is enrolling ≈5750 patients with HFpEF (ejection fraction >40%), with and without type 2 diabetes, who are randomized to receive placebo or empagliflozin 10 mg/day, which is added to all appropriate treatments for HFpEF and co-morbidities. Study aims: The primary endpoint is the time-to-first-event analysis of the combined risk for cardiovascular death or hospitalization for heart failure. The trial will also evaluate the effects of empagliflozin on renal function, cardiovascular death,. all-cause mortality and recurrent hospitalization events, and will assess a wide range of biomarkers that reflect important pathophysiological mechanisms that may drive the evolution of HFpEF. The EMPEROR-Preserved Trial is well positioned to determine if empagliflozin can have a meaningfu

Published
2019

31. Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry

Author

Cowie, M.R. Schöpe, J. Wagenpfeil, S. Tavazzi, L. Böhm, M. Ponikowski, P. Anker, S.D. Filippatos, G.S. Komajda, M. QUALIFY Investigators

Subjects
cardiovascular diseases
Abstract

Aims: Failure to prescribe key medicines at evidence-based doses is associated with increased mortality and hospitalization for patients with Heart Failure with reduced Ejection Fraction (HFrEF). We assessed titration patterns of guideline-recommended HFrEF medicines internationally and explored associations with patient characteristics in the global, prospective, observational, longitudinal registry. Methods and results: Data were collected from September 2013 through December 2014, with 7095 patients from 36 countries [>18 years, previous HF hospitalization within 1–15 months, left ventricular ejection fraction (LVEF) ≤ 40%] enrolled, with dosage data at baseline and up to 18 months from 4368 patients. In 4368 patients (mean age 63 ± 17 years, 75% male) ≥ 100% target doses at baseline: 30.6% (ACEIs), 2.9% (ARBs), 13.9% (BBs), 53.8% (MRAs), 26.2% (ivabradine). At final follow-up, ≥100% target doses achieved in more patients for ACEI (34.8%), BB (18.0%), and ivabradine (30.5%) but unchanged for ARBs (3.2%) and MRAs (53.7%). Adjusting for baseline dosage, uptitration during follow-up was more likely with younger age, higher systolic blood pressure, and in absence of chronic kidney disease or diabetes for ACEIs/ARBs; younger age, higher body mass index, higher heart rate, lower LVEF, and absence of coronary artery disease for BBs. For ivabradine, uptitration was more likely with higher resting heart rate. Conclusions: The international QUALIFY Registry suggests that few patients with HFrEF achieve target doses of disease-modifying medication, especially older patients and those with co-morbidity. Quality improvement initiatives are urgently required. © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Published
2021

32. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Author

Bhatt, D. L., Szarek, M., Gabriel Steg, P., Cannon, C. P., Leiter, L. A., Mcguire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., Lund, L. H., Komajda, M., Testani, J. M., Wilcox, C. S., Ponikowski, P., Lopes, R. D., Verma, S., Lapuerta, P., Pitt, B, Volpe, M., for the SOLOIST-WHF Trial Investigators, and Cardiovascular Centre (CVC)

Subjects
Male, SAXAGLIPTIN, 030204 cardiovascular system & hematology, Saxagliptin, law.invention, MELLITUS, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, Glycosides, 030212 general & internal medicine, RISK, SGLT2 INHIBITOR, OUTCOMES, EMPAGLIFLOZIN, Acute kidney injury, General Medicine, Acute Kidney Injury, Middle Aged, Hospitalization, Heart Failure/complications, type 2, Cardiovascular Diseases, diabetes mellitus, Cardiology, Female, Hypotension, OUTPATIENTS, medicine.medical_specialty, Glycosides/adverse effects, Hypotension/chemically induced, 03 medical and health sciences, Sodium-Glucose Transporter 1, Double-Blind Method, Acute Kidney Injury/chemically induced, Internal medicine, Diabetes mellitus, medicine, Empagliflozin, Humans, In patient, Sodium-Glucose Transporter 2 Inhibitors, Hospitalization/statistics & numerical data, Aged, Heart Failure, business.industry, Cardiovascular Diseases/epidemiology, Diabetes Mellitus, Type 2/complications, MORTALITY, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, medicine.disease, CARDIOVASCULAR EVENT RATES, Clinical trial, Sodium-Glucose Transporter 1/antagonists & inhibitors, Diabetes Mellitus, Type 2, chemistry, Heart failure, business, acute kidney injury, aged, cardiovascular diseases, diabetes mellitus, type 2, double-blind method, female, glycosides, heart failure, hospitalization, humans, hypotension, male, middle aged, sodium-glucose transporter 1, sodium-glucose transporter 2 inhibitors
Abstract

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown.METHODS: We performed a multicenter, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure were randomly assigned to receive sotagliflozin or placebo. The primary end point was the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (first and subsequent events). The trial ended early because of loss of funding from the sponsor.RESULTS: A total of 1222 patients underwent randomization (608 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 months; the first dose of sotagliflozin or placebo was administered before discharge in 48.8% and a median of 2 days after discharge in 51.2%. Among these patients, 600 primary end-point events occurred (245 in the sotagliflozin group and 355 in the placebo group). The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.85; PCONCLUSIONS: In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).

Published
2021
Full Text
View/download PDF

33. Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

Author

Packer, M. Anker, S.D. Butler, J. Filippatos, G. Ferreira, J.P. Pocock, S.J. Carson, P. Anand, I. Doehner, W. Haass, M. Komajda, M. Miller, A. Pehrson, S. Teerlink, J.R. Brueckmann, M. Jamal, W. Zeller, C. Schnaidt, S. Zannad, F.

Abstract

Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, with or without diabetes, but additional data are needed about the effect of the drug on inpatient and outpatient events that reflect worsening heart failure. Methods: We randomly assigned 3730 patients with class II to IV heart failure with an ejection fraction of ≤40% to double-blind treatment with placebo or empagliflozin (10 mg once daily), in addition to recommended treatments for heart failure, for a median of 16 months. We prospectively collected information on inpatient and outpatient events reflecting worsening heart failure and prespecified their analysis in individual and composite end points. Results: Empagliflozin reduced the combined risk of death, hospitalization for heart failure or an emergent/urgent heart failure visit requiring intravenous treatment (415 versus 519 patients; empagliflozin versus placebo, respectively; hazard ratio [HR], 0.76; 95% CI, 0.67-0.87; P

Published
2021

34. Association study and subsequent analyses revealed two new key players in DCM

Author

Garnier, S, Harakalova, M, Weiss, S, Mokry, M, Isnard, R, Duboscq-Bidot, L, Komajda, M, Cambien, F, Deleuze, J-F, Dörr, M, Asselbergs F, W, Villard, E, Trégouët, D-A, Charron, P, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Utrecht University [Utrecht], Universität Greifswald - University of Greifswald, Sorbonne Université (SU), Centre National de Recherche en Génomique Humaine (CNRGH), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratory of Excellence GENMED [Paris] (Medical Genomics), University of Medicine Greifswald, German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience

Published
2020

36. Genome wide association analysis in dilated cardiomyopathy reveals two new key players in systolic heart failure on chromosomes 3p25.1 and 22q11.23

Author

Garnier, S., primary, Harakalova, M., additional, Stefan, W., additional, Michal, M., additional, Isnard, R., additional, Duboscq-Bidot, L., additional, Komajda, M., additional, Cambien, F., additional, Deleuze, J., additional, Dörr, M., additional, Asselbergs, F., additional, Villard, E., additional, Trégouët, D.A., additional, and Charron, P., additional

Published
2021
Full Text
View/download PDF

38. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure

Author

OʼConnor, C. M., Starling, R. C., Hernandez, A. F., Armstrong, P. W., Dickstein, K., Hasselblad, V., Heizer, G. M., Komajda, M., Massie, B. M., McMurray, J. J.V., Nieminen, M. S., Reist, C. J., Rouleau, J. L., Swedberg, K., Adams, K. F., Jr., Anker, S. D., Atar, D., Battler, A., Botero, R., Bohidar, N. R., Butler, J., Clausell, N., Corbalán, R., Costanzo, M. R., Dahlstrom, U., Deckelbaum, L. I., Diaz, R., Dunlap, M. E., Ezekowitz, J. A., Feldman, D., Felker, G. M., Fonarow, G. C., Gennevois, D., Gottlieb, S. S., Hill, J. A., Hollander, J. E., Howlett, J. G., Hudson, M. P., Kociol, R. D., Krum, H., Laucevicius, A., Levy, W. C., Méndez, G. F., Metra, M., Mittal, S., Oh, B.-H., Pereira, N. L., Ponikowski, P., Wilson, W. H., Tanomsup, S., Teerlink, J. R., Triposkiadis, F., Troughton, R. W., Voors, A. A., Whellan, D. J., Zannad, F., and Califf, R. M.

Published
2011

39. Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform: Report of a policy conference of the European Society of Cardiology†

Author

Fraser, Alan G., Daubert, Jean-Claude, Van de Werf, Frans, Estes, N.A. Mark, III, Smith, Sidney C., Jr, Krucoff, Mitchell W., Vardas, Panos E., Komajda, Michel, Anker, SD, Auricchio, A, Bailey, S, Bonhoeffer, P, Borggrefe, M, Brodin, L-Å, Bruining, N, Buser, P, Butchart, E, Calle Gordo, J, Cleland, J, Danchin, N, Daubert, JC, Degertekin, M, Demade, I, Denjoy, N, Derumeaux, G, Di Mario, C, Dickstein, K, Dudek, D, Estes, NA, Farb, A, Flotats, A, Fraser, AG, Gueret, P, Israel, C, James, S, Kautzner, J, Komajda, M, Krucoff, MW, Lombardi, M, Marwick, T, Mioulet, M, OʼKelly, S, Perrone-Filardi, P, Rosano, G, Rosenhek, R, Sabate, M, Smith, SC, Swahn, E, Tavazzi, L, Van de Werf, F, van der Velde, E, van Herwerden, L, Vardas, PE, Voigt, J-U, Weaver, D, and Wilmshurst, P.

Published
2011
Full Text
View/download PDF

43. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Author

Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., Huikuri, H. V., Johansson, I., Juni, P., Lettino, M., Marx, N., Mellbin, L. G., Ostgren, C. J., Rocca, Bianca, Roffi, M., Sattar, N., Seferovic, P. M., Sousa-Uva, M., Valensi, P., Wheeler, D. C., Piepoli, M. F., Birkeland, K. I., Adamopoulos, S., Ajjan, R., Avogaro, A., Baigent, C., Brodmann, M., Bueno, H., Ceconi, C., Chioncel, O., Coats, A., Collet, J. -P., Collins, P., Cosyns, B., Di Mario, C., Fisher, M., Fitzsimons, D., Halvorsen, S., Hansen, D., Hoes, A., Holt, R. I. G., Home, P., Katus, H. A., Khunti, K., Komajda, M., Lambrinou, E., Landmesser, U., Lewis, B. S., Linde, C., Lorusso, R., Mach, F., Mueller, C., Neumann, F. -J., Persson, F., Petersen, S. E., Petronio, A. S., Richter, D. J., Rosano, G. M. C., Rossing, P., Ryden, L., Shlyakhto, E., Simpson, I. A., Touyz, R. M., Wijns, W., Wilhelm, M., Williams, B., Windecker, S., Dean, V., Gale, C. P., Hindricks, G., Iung, B., Leclercq, C., Merkely, B., Zelveian, P. H., Scherr, D., Jahangirov, T., Lazareva, I., Shivalkar, B., Naser, N., Gruev, I., Milicic, D., Petrou, P. M., Linhart, A., Hildebrandt, P., Hasan-Ali, H., Marandi, T., Lehto, S., Mansourati, J., Kurashvili, R., Siasos, G., Lengyel, C., Thrainsdottir, I. S., Aronson, D., Di Lenarda, A., Raissova, A., Ibrahimi, P., Abilova, S., Trusinskis, K., Saade, G., Benlamin, H., Petrulioniene, Z., Banu, C., Magri, C. J., David, L., Boskovic, A., Alami, M., Liem, A. H., Bosevski, M., Svingen, G. F. T., Janion, M., Gavina, C., Vinereanu, D., Nedogoda, S., Mancini, T., Ilic, M. D., Fabryova, L., Fras, Z., Jimenez-Navarro, M. F., Norhammar, A., Lehmann, R., Mourali, M. S., Ural, D., Nesukay, E., Chowdhury, T. A., Clinical sciences, Cardio-vascular diseases, Cardiology, Human Physiology and Special Physiology of Physical Education, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), University of Zurich, and Cosentino, Francesco

Subjects
Settore MED/09 - Medicina Interna, Epidemiology, [SDV]Life Sciences [q-bio], 10265 Clinic for Endocrinology and Diabetology, Psychological intervention, Disease, Impaired glucose tolerance, Diabetes mellitus, Health care, risk factors, Guidelines, cardiovascular diseases, cardiovascular risk assessment, diabetes mellitus, epidemiology, impaired glucose tolerance, patient management, patient-centred care, pharmacological treatment, prevention, revascularization, Prediabetes, ComputingMilieux_MISCELLANEOUS, Societies, Medical, ddc:616, Cardiovascular risk assessment, 3. Good health, Europe, Cardiovascular diseases, Pre diabetes, Practice Guidelines as Topic, Cardiology and Cardiovascular Medicine, Pharmacological treatment, medicine.medical_specialty, Patient management, Patient-centred care, Prevention, Revascularization, Risk factors, Settore BIO/14 - FARMACOLOGIA, Cardiology, 610 Medicine & health, 2705 Cardiology and Cardiovascular Medicine, Prediabetic State, medicine, Humans, business.industry, medicine.disease, Diabetes Mellitus, Type 2, Family medicine, business
Abstract

This is the second iteration of the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) joining forces to write guidelines on the management of diabetes mellitus (DM), pre-diabetes, and cardiovascular disease (CVD), designed to assist clinicians and other healthcare workers to make evidence-based management decisions. The growing awareness of the strong biological relationship between DM and CVD rightly prompted these two large organizations to collaborate to generate guidelines relevant to their joint interests, the first of which were published in 2007. Some assert that too many guidelines are being produced but, in this burgeoning field, five years in the development of both basic and clinical science is a long time and major trials have reported in this period, making it necessary to update the previous Guidelines.

Published
2020
Full Text
View/download PDF

44. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure

Author

Seferović, P.M. Coats, A.J.S. Ponikowski, P. Filippatos, G. Huelsmann, M. Jhund, P.S. Polovina, M.M. Komajda, M. Seferović, J. Sari, I. Cosentino, F. Ambrosio, G. Metra, M. Piepoli, M. Chioncel, O. Lund, L.H. Thum, T. De Boer, R.A. Mullens, W. Lopatin, Y. Volterrani, M. Hill, L. Bauersachs, J. Lyon, A. Petrie, M.C. Anker, S. Rosano, G.M.C.

Abstract

Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and associated with considerable morbidity and mortality. Significant advances have recently occurred in the treatment of T2DM, with evidence of several new glucose-lowering medications showing either neutral or beneficial cardiovascular effects. However, some of these agents have safety characteristics with strong practical implications in HF [i.e. dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RA), and sodium–glucose co-transporter type 2 (SGLT-2) inhibitors]. Regarding safety of DPP-4 inhibitors, saxagliptin is not recommended in HF because of a greater risk of HF hospitalisation. There is no compelling evidence of excess HF risk with the other DPP-4 inhibitors. GLP-1 RAs have an overall neutral effect on HF outcomes. However, a signal of harm suggested in two small trials of liraglutide in patients with reduced ejection fraction indicates that their role remains to be defined in established HF. SGLT-2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) have shown a consistent reduction in the risk of HF hospitalisation regardless of baseline cardiovascular risk or history of HF. Accordingly, SGLT-2 inhibitors could be recommended to prevent HF hospitalisation in patients with T2DM and established cardiovascular disease or with multiple risk factors. The recently completed trial with dapagliflozin has shown a significant reduction in cardiovascular mortality and HF events in patients with HF and reduced ejection fraction, with or without T2DM. Several ongoing trials will assess whether the results observed with dapagliflozin could be extended to other SGLT-2 inhibitors in the treatment of HF, with either preserved or reduced ejection fraction, regardless of the presence of T2DM. This position paper aims to summarise relevant clinical trial evidence concerning the role and safety of new glucose-lowering therapies in patients with HF. © 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results